Verastem (VSTM) Tax Provisions (2024 - 2026)
Verastem (VSTM) posted quarterly Tax Provisions of -$44.0 million for Q4 2025, down 22094.5% year-over-year from N/an in Q4 2024, and down 22094.5% quarter-over-quarter from $200000.0 in Q4 2024.
Powered by 
Analysis
Verastem (VSTM) Tax Provisions (2024 - 2026) Analysis & Trends
Verastem's Tax Provisions history runs 2 years deep, the most recent figure standing at -$44.0 million for Q4 2025.
- In Q4 2025, Tax Provisions fell 22094.5% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$44.0 million (down 22094.5% YoY), while the FY2025 annual figure was -$44.0 million, down 22094.5% from the prior year.
- Tax Provisions for Q4 2025 stood at -$44.0 million, down from $200000.0 in the prior quarter.
- The five-year high for Tax Provisions was $200000.0 in Q4 2024, with the low at -$44.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Verastem | 789.92 Mn | 653.56 Mn | 36.32 Mn | 816,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 816,000.00 |
| Dec 31, 2025 | -43.99 Mn |
| Dec 31, 2024 | 200,000.00 |